Jubilant Life Sciences today said its subsidiary Jubilant Pharma has completed the acquisition of the US radiopharmacy business of Triad Isotopes Inc. Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies. Jubilant Pharma Ltd (JPL), through one of its wholly owned subsidiaries, has successfully completed today the acquisition of the US radiopharmacy business of Triad Isotopes Inc, Jubilant Life Sciences said in a BSE filing. “The acquisition adds significant scale to our niche radiopharmaceutical business in the specialty pharma injectibles segment complementing our strategy of being a leading nuclear medicine player,” the company’s Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said.
The acquired radiopharmacies will continue to operate independently under the brand name of Triad Isotopes. The acquisition is funded through JPL’s internal accruals with no increase in debt for Jubilant Life Sciences, the company said.